News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aptuit, Inc. Launches New Tag Line to Redefine and Reinforce Brand


1/18/2013 9:27:33 AM

Greenwich, CT, January 17, 2013 – Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced the introduction of “Uncommon Expertise. Exceptional Results.” as the new corporate tag line to serve as an accompanying message to the corporate logo.

Mr. Needleman stated, “For the purpose of emphasizing the core essence of what Aptuit represents to clients, we examined the many ways that we could concisely express just what we stand for. We want our clients to know that it is our uncommon expertise that gives them the assurance of exceptional results.”

Mr. Needleman explained that there’s a real point of difference between Aptuit and other CROs; namely, that Aptuit combines all the capabilities of a CRO with the efficiency of an integrated, large pharma R&D engine. “From drug discovery to drug development, our services coalesce to provide an integrated, collaborative response to advancing the success of our client’s molecule. Our responsiveness includes access as needed to the expertise of a vast number of scientists at our key locations around the world. These scientists have had experience in working with emerging biotechs as well as large pharmaceutical companies and many of them have worked within a large pharma environment for a substantial number of years. Significantly, they have expertise across a range of therapeutic areas, the same areas of discovery and development that challenge our clients.”

Mr. Needleman stressed that when Aptuit teams of multidisciplinary, expert scientists collaborate in integrated efforts from a single Aptuit site, or coordinate their knowledge among several sites, successful results are predictable.

“What’s not predictable in any project are the unexpected findings that may surface that threaten to forestall or interfere with the process. It is at these junctures that clients experience Aptuit’s ‘uncommon expertise’ at its fullest since we operate in a spirit of openness and transparency. Our goal is to ensure that clients are never in the dark about what’s happening and what the impact may be, which we can mitigate because we employ a flexible strategy. Aptuit clients are aware of what’s going on – under the leadership of project management and through our overriding culture of service that goes above and beyond. They experience what we do to identify obstacles early on; they see firsthand how our commitment to straightforward and honest communications is a major part of ensuring exceptional results,” concluded Mr. Needleman.

For more information, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com.

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Sterile Fill Finish & Formulation Development, Oral Dosage Form Development & Manufacture, Clinical Sciences, Consulting and Aptuit INDiGOÒ (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES